The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,865 million by 2026, registering a CAGR of 7.5% from 2019 to 2026. 

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others.  

Get more information on this report : Request Sample Pages

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the growth of the market. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities during the forecast period.    

Antihyperlipidemic Drugs Market Segmentation  

The antihyperlipidemic drugs market size is studied based on segments, drug class and region to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to drug class, statins occupied the largest antihyperlipidemic drugs market share in 2018, owing to surge in the incidence of cardiovascular disorders. Furthermore, statins reduce the risk associated with heart attacks which is another major factor that contributes to the growth of the market. Moreover, PCSK9 inhibitors is expected to register the fastest growth during the forecast period, owing to the benefits offered such as drastic reduction of LDL levels in the blood. The other factors that boost the antihyperlipidemic drugs market growth include the surge in the geriatric population and rise in healthcare expenditure across the globe. In addition, the other factors which boost the growth of the market include the additional benefits offered by the statins such as improved endothelial function, enhance the stability of atherosclerotic plaques, and reduce the amount of inflammation & damage done to cells due to oxidative stress.

[DRUGCLASSGRAPH]

Get more information on this report : Request Sample Pages

By region, North America accounted for the major antihyperlipidemic drugs market share in 2018, and is expected to continue this trend due to easy availability of the antihyperlipidemic drugs. Moreover, surge in sedentary lifestyle in the region is another major factor that contributes to the growth of the market. Furthermore, surge in the obese population is another major factor that fuels the growth of the antihyperlipidemic drugs market. In addition, the presence of major key players such as Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. and others is another major factor that fuels the growth of antihyperlipidemic drugs market in the region. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of antihyperlipidemic drugs. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, Malaysia, and others.

[REGIONGRAPH]

Get more information on this report : Request Sample Pages

The global antihyperlipidemic drugs market is highly competitive and the prominent players in the market have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Key Benefits for Stakeholders:

• This report entails a detailed quantitative analysis along with the current global antihyperlipidemic drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The antihyperlipidemic drugs market forecast is studied from 2019 to 2026. 
• The market size and estimations are based on a comprehensive analysis of key developments in the industry. 
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

 Key Market Segments

• By Drug Class
  • Statins
  • Bile Acid Sequestrants
  • Cholesterol Absorption Inhibitors
  • Fibric Acid Derivatives
  • PCSK9 Inhibitors
  • Combination
  • Others
• By Region
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

 
Key Market Players

• AstraZeneca plc
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Dr. Reddy’s Laboratories Ltd
• Mylan N.V
• SANOFI S.A.
• Daiichi Sankyo Company, Limited
• Amgen Inc.
• ABBVIE INC.
• Merck & Co., Inc

CHAPTER 1: INTRODUCTION

1.1. Report description 
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping antihyperlipidemic industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Presence of guidelines recommending the use of statins
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in prevalence of hyperlipidemia across  the globe

3.4.2. Restraint

3.4.2.1. Upcoming patent expirations of drugs

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analyses

CHAPTER 4: ANTIHYPERLIPIDEMIC DRUGS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Statins

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country

4.3. Bile Acid Sequestrants

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country

4.5. Fibric Acid Derivatives

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

4.6. PCSK9 Inhibitors

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country

4.7. Combination

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis by country

4.8. Others

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis by country

CHAPTER 5: ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION

5.1. Overview

5.1.1. Market size and forecast

5.2. North America

5.2.1. Key market trends and opportunities
5.2.2. Market analysis, by country

5.2.2.1. U.S.

5.2.2.1.1. U.S. market size and forecast, by drug class

5.2.2.2. Canada

5.2.2.2.1. Canada market size and forecast, by drug class

5.2.2.3. Mexico

5.2.2.3.1. Mexico market size and forecast, by drug class

5.2.3. North America market size and forecast, by drug class

5.3. Europe

5.3.1. Key market trends and opportunities
5.3.2. Market analysis, by country

5.3.2.1. Germany

5.3.2.1.1. Germany market size and forecast, by drug class

5.3.2.2. France

5.3.2.2.1. France market size and forecast, by drug class

5.3.2.3. UK

5.3.2.3.1. UK market size and forecast, by drug class

5.3.2.4. Italy

5.3.2.4.1. Italy market size and forecast, by drug class

5.3.2.5. Rest of Europe

5.3.2.5.1. Rest of Europe market size and forecast, by drug class

5.3.3. Europe market size and forecast, by drug class

5.4. Asia-Pacific

5.4.1. Key market trends and opportunities
5.4.2. Market analysis, by country

5.4.2.1. Japan

5.4.2.1.1. Japan market size and forecast, by drug class

5.4.2.2. China

5.4.2.2.1. China market size and forecast, by drug class

5.4.2.3. India

5.4.2.3.1. India market size and forecast, by drug class

5.4.2.4. Rest of Asia-Pacific

5.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class

5.4.3. Asia-Pacific market size and forecast, by drug class

5.5. LAMEA

5.5.1. Key market trends and opportunities
5.5.2. Market analysis, by country

5.5.2.1. Brazil

5.5.2.1.1. Brazil market size and forecast, by drug class

5.5.2.2. South Africa

5.5.2.2.1. South Africa market size and forecast, by drug class

5.5.2.3. Saudi Arabia

5.5.2.3.1. Saudi Arabia market size and forecast, by drug class

5.5.2.4. Rest of LAMEA

5.5.2.4.1. Rest of LAMEA market size and forecast, by drug class

5.5.3. LAMEA market size and forecast, by drug class

CHAPTER 6: COMPANY PROFILES

6.1. ABBVIE INC.

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio
6.1.5. Business performance

6.2. Amgen Inc.

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Business performance
6.2.6. Key strategic moves and developments

6.3. AstraZeneca plc

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Business performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Business performance

6.5. Daiichi Sankyo Company, Limited

6.5.1. Company overview
6.5.2. Operating business segments
6.5.3. Product portfolio
6.5.4. Business performance

6.6. Dr. Reddy’s Laboratories Ltd

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Business performance

6.7. Merck & Co., Inc

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Business performance

6.8. Mylan N.V

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Business performance

6.9. Pfizer Inc.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance

6.10. SANOFI S.A.

6.10.1. Company overview
6.10.2. Operating business segments
6.10.3. Product portfolio
6.10.4. Business performance
6.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 01. GLOBAL ANTIHYPERLIPIDEMIC DRUGS MARKET, BY DRUG CLASS, 2018-2026 ($MILLION )
TABLE 02. STATINS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. BILE ACID SEQUESTRANTS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CHOLESTEROL ABSORPTION INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. FIBRIC ACID DERIVATIVES ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. PCSK9 INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. COMBINATION ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTHERS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. ANTIHYPERLIPIDEMIC DRUGS MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 10. NORTH AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 11. U.S. ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 12. CANADA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 13. MEXICO ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 14. NORTH AMERICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 15. EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 16. GERMANY ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. FRANCE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 18. UK ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 19. ITALY ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 20. REST OF EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 21. EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 22. ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 23. JAPAN ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. CHINA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 25. INDIA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. REST OF ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 27. ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 28. LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 29. BRAZIL ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. SOUTH AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 31. SAUDI ARABIA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 32. REST OF LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 33. LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 34. ABBVIE: COMPANY SNAPSHOT
TABLE 35. ABBVIE: OPERATING BUSINESS SEGMENTS
TABLE 36. ABBVIE: PRODUCT PORTFOLIO
TABLE 37. AMGEN: COMPANY SNAPSHOT
TABLE 38. AMGEN: PRODUCT BUSINESS SEGMENT
TABLE 39. AMGEN: PRODUCT PORTFOLIO
TABLE 40. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 41. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 42. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 43. BMS: COMPANY SNAPSHOT
TABLE 44. BMS: OPERATING SEGMENTS
TABLE 45. BMS: PRODUCT PORTFOLIO
TABLE 46. DAIICHI-SANKYO.: COMPANY SNAPSHOT
TABLE 47. DAIICHI-SANKYO.: OPERATING BUSINESS SEGMENTS
TABLE 48. DAIICHI-SANKYO.: PRODUCT PORTFOLIO
TABLE 49. DR.REDDY'S: COMPANY SNAPSHOT
TABLE 50. DR. REDDY’S: OPERATING BUSINESS SEGMENTS
TABLE 51. DR. REDDY’S: PRODUCT PORTFOLIO
TABLE 52. MERCK: COMPANY SNAPSHOT
TABLE 53. MERCK: OPERATING SEGMENTS
TABLE 54. MERCK: PRODUCT PORTFOLIO
TABLE 55. MYLAN: COMPANY SNAPSHOT
TABLE 56. MYLAN: OPERATING SEGMENTS
TABLE 57. MYLAN: PRODUCT PORTFOLIO
TABLE 58. PFIZER: COMPANY SNAPSHOT
TABLE 59. PFIZER: OPERATING SEGMENTS
TABLE 60. PFIZER: PRODUCT PORTFOLIO
TABLE 61. SANOFI: COMPANY SNAPSHOT
TABLE 62. SANOFI: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL ANTIHYPERLIPIDEMIC DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. IMPACT ANALYSES, ANTIHYPERLIPIDEMIC DRUGS MARKET
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF STATINS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BILE ACID SEQUESTRANTS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CHOLESTEROL ABSORPTION INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF FIBRIC ACID DERIVATIVES ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PCSK9 INHIBITORS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF COMBINATION ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIHYPERLIPIDEMIC DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. U.S. ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 18. CANADA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 19. MEXICO ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 20. GERMANY ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 21. FRANCE ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 22. UK ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 23. ITALY ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 24. REST OF EUROPE ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 25. JAPAN ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 26. CHINA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 27. INDIA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 28. REST OF ASIA-PACIFIC ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 29. BRAZIL ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 30. SOUTH AFRICA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 31. SAUDI ARABIA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 32. REST OF LAMEA ANTIHYPERLIPIDEMIC DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 33. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 34. ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 35. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 37. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 43. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018(%)
FIGURE 44. DR. REDDY’S: NET SALES, 2016–2018 ($MILLION)
FIGURE 45. DR. REDDY’S: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 46. DR. REDDY’S: REVENUE SHARE BY REGION, 2018(%)
FIGURE 47. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 48. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 49. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 50. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 52. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 55. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. SANOFI: REVENUE SHARE BY REGION, 2018(%)